| Literature DB >> 26546156 |
G Anupa1, M A Bhat2, A K Srivastava3, J B Sharma4, N Mehta5, Asmita Patil6, Jayasree Sengupta7, D Ghosh8.
Abstract
BACKGROUND: Human placental villous cytotrophoblasts exhibit relative externalization of negatively charged moieties to the outer leaflet of the plasma membrane during the time of syncytialization rendering their reactivity to positively charged cationic antimicrobial peptides (CAMPs) during the window of implantation and early placentation. Vaginal administration of a synthetic CAMP, Ala(8,13,18)-magainin II amide (AMA) inhibited blastocyst implantation and early placentation in monkeys. Furthermore, the administration of AMA resulted in significant inhibition of cell differentiation, enhancement in apoptosis and loss of viability in first trimester placental villous cytotrophoblasts in primary culture. The present study examines the effect of in vitro application of different doses (0, 1, 10, 100, 1000 ng/ml) of AMA on the secreted cytokine profiles of cytotrophoblasts obtained from placental villi samples (n = 13) collected during 8-9 weeks of gestation and grown on three-dimensional collagen matrix in vitro.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26546156 PMCID: PMC4636767 DOI: 10.1186/s12958-015-0119-8
Source DB: PubMed Journal: Reprod Biol Endocrinol ISSN: 1477-7827 Impact factor: 5.211
Fig. 1Immunocytochemical characterization of isolated villous cytotrophoblast cells. Isolated cells were allowed to attach to the collagen biomatrix and immunostained for cytokeratin 7 (CK-7; a green; 97 % positive), vitronectin receptor (CD51; b green; 95 % negative) and βhCG (c red; 92 % positive), vimentin (d red; 99 % negative), vWF (e red; 99 % negative). Nuclei are counterstained with DAPI (blue). Bar = 40 μm
Concentrationa of consistentlyb secreted cytokines in conditioned medium of isolated cytotrophoblasts exposed to AMA for 24 h
| Cytokine (Alias) | Concentration (ng/ml) of AMA applied | ||||
|---|---|---|---|---|---|
| 0 | 1 | 10 | 100 | 1000 | |
| CCL2 (MCP1) | 96.8 (3.2) | 80.8 (10.2) | 78.7 (14.6) | 73.1** (5.2) | 74.5** (5.9) |
| CCL3 (MIP1Α) | 49.0 (2.9) | 53.2 (5.2) | 53.3 (5.2) | 44.4 (3.4) | 38.5* (2.1) |
| CCL4 (MIP1B) | 298.0 (22.1) | 298.3 (12.9) | 350.6 (35.2) | 265.2* (12.6) | 260.2** (12.4) |
| CCL5 (RANTES) | 362.4 (20.7) | 367.9 (30.3) | 362.4 (21.3) | 332.0* (17.9) | 309.7* (11.6) |
| CLEC11A (SCGFB) | 592.1 (58.9) | 602.9 (72.0) | 609.3 (94.9) | 559.7 (68.7) | 544.9 (68.4) |
| CXCL1 (GROΑ) | 678.0 (61.2) | 688.5 (22.9) | 649.2 (33.4) | 529.4** (29.3) | 527.2** (30.6) |
| CXCL9 (MIG) | 113.2 (10.4) | 112.9 (16.0) | 114.2 (12.6) | 97.1 (15.4) | 99.4 (17.9) |
| CXCL10 (IP-10) | 152.7 (12.5) | 143.7 (14.2) | 119.5 (28.0) | 129.9 (29.9) | 155.21 (10.74) |
| CXCL12 (SDF-1) | 87.5 (14.1) | 89.6 (26.7) | 99. 9 (27.5) | 83.8 (13.3) | 79.6 (23.5) |
| FGF2 (basic FGF) | 4.4 (0.3) | 4.9 (0.2) | 4.8 (0.2) | 4.1 (0.9) | 3.2* (0.5) |
| GCSF (CSF-3) | 2307.5 (101.6) | 2260.1 (138.4) | 2242.3 (160.1) | 2127.0 (177.3) | 1946.0 (250.6) |
| HGF (SF) | 12501.5 (1648.7) | 10638.3 (1955.3) | 10935.2 (1194.5) | 9930.7 (874.5) | 9920.1 (834.8) |
| IFNA2 | 4.9 (1.9) | 11.1 (5.4) | 4.5 (0.9) | 4.9 (2.9) | 4.7 (1.6) |
| IL1A | 113.4 (14.9) | 106.0(15.5) | 112.8 (17.0) | 128.7 (18.2) | 120.6 (13.4) |
| IL1B | 353.0 (23.4) | 333.1 (34.2) | 322.7 (31.6) | 313.5* (26.9) | 302.2** (10.6) |
| IL-1RA | 32.9 (2.6) | 30.2 (6.1) | 27.8 (6.5) | 29.5 (1.0) | 28.8 (3.0) |
| IL-2RA (CD25) | ND | ND | 2.3 | 2.2 | 2.9 |
| IL6 (IFNΒ2) | 752.7 (41.8) | 736.2 (40.1) | 704.3 (31.3) | 611.5** (22.6) | 587.8** (26.1) |
| IL8 (CXCL8) | 11779.0 (2146.6) | 12706.4 (2868.5) | 16701.7 (4785.2) | 14902.2 (4615.2) | 8302.9* (2435.9) |
| IL9 (HP40) | 0.6 (0.3) | 0.3 (0.2) | 0.3 (0.2) | 0.4 (0.2) | 0.3 (0.2) |
| IL16 (LCF) | 11.4(3.9) | 11.0 (4.8) | 18.7* (2.4) | 18.3* (2.6) | 18.8* (2.2) |
| IL18 (IGIF) | 28.9 (2.8) | 30.2 (2.3) | 28.0 (3.0) | 25.2 (1.7) | 29.2 (1.7) |
| LIF (DIA) | 2.8 (1.2) | 2.9 (1.4) | 2.9 (1.3) | 2.8 (1.2) | 3.1 (1.3) |
| MCSF (CSF1) | 174.2 (16.2) | 125.9* (23.6) | 123.7* (21.3) | 121.6* (27.9) | 125.6** (7.4) |
| MIF (MMIF) | 2919.2 (178.5) | 2790.7 (211.2) | 2708.6 (260.7) | 2231.1* (261.3) | 2154.2** (143.1) |
| TNF (TNF alpha) | 0.6 (0.3) | 0.5 (0.2) | 0.4 (0.2) | 0.4 (0.2) | 0.4 (0.3) |
| VEGF-A (VPF) | 0.3 (0.1) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) | 0.2 (0.1) |
Values are shown as means with SDs in brackets. apg/mg of Bradford protein. Note that concentrations were estimated in terms of pg per unit mg of secreted protein (w/w) to avoid any bias in mass per unit volume. b ≥ 0.1 pg/mg of Bradford protein detected in at least 80 % samples. induced. *P < 0.05, **P < 0.01 as compared to control. ND, values <0.1 pg/mg Bradford protein
Fig. 2The linearized profiles of putatively important cytokines in the conditioned medium of villous cytotrophoblasts in primary culture following the administration of different doses (0, 1, 10, 100, 1000 ng/ml) of AMA. Linear regressions were obtained from individual values, taking the estimated maximum values as 100 % for obtaining dose-dependent profiles. The twelve (12) cytokines were selected based on enrichment analysis. **P < 0.01. *P < 0.05
Fig. 3Representative Western immunoblots of CCL4 and TNF from conditioned media without cells (Control, − cells/+AMA), and with cytotrophoblast cells grown in primary culture on collagen biomatrix (+ cells) with AMA (1000 ng/ml) and without AMA (Control, +cells). Media containing 20 μg of Bradford proteins were subjected to electrophoretic separation followed by immunoblot analysis. The log transformed measures of optical densities for each target antigen were calculated as per cent of total integrated optical densities for total protein loaded as described in the Methods section. The values for CCL4 in specific experiment were 11.8 (Control, +cells), 6.7 (AMA, +cells) and 0.7 (Control, −cells/+AMA), and for TNF were 1.6 (Control, +cells), 1.2 (AMA, +cells) and 0.8 (Control, −cells/+AMA) per cent of integrated optical densities, resepectively
Comparative profiles of immunopositive proteins in medium and respective transcripts in cells for selected cytokines in primary cultures with (1000 ng/ml) and without AMA
| Name of cytokine | Mean ± SD ( | |||
|---|---|---|---|---|
| Concentration in conditioned mediuma | Relative level of transcript in cellsb | |||
| Control | AMA | Control | AMA | |
| CCL4 (MIP1B) | 298.0 | 260.2** | 2.5 | 2.6 |
| ±22.1 | ±12.4 | ±0.7 | ±0.9 | |
| CCL5 (RANTES) | 362.4 | 309.7* | 5.2 | 5.8 |
| ±20.7 | ±11.6 | ±2.7 | ±2.1 | |
| IL1A | 113.4 | 120.6 | 2.9 | 3.6 |
| ±14.9 | ±13.4 | ±2.4 | ±2.1 | |
| IL1B | 353.0 | 302.2** | 2.5 | 2.9 |
| ±23.4 | ±10.6 | ±1.1 | ±1.5 | |
| IL-2RA | 0.08c | 2.9*** | 7.3 | 9.5** |
| ±0.03 | ±0.1 | ±0.1 | ±0.3 | |
| IL6 | 752.7 | 587.8** | 5.8 | 6.9 |
| ±41.8 | ±21.1 | ±1.2 | ±1.8 | |
| IL16 | 11.4 | 18.8* | 7.5 | 8.8** |
| ±3.9 | ±2.2 | ±0.1 | ±0.2 | |
| MIF | 2919.2 | 2154.2 | 9.8 | 8.3* |
| ±178.5 | ±143.0 | ±0.6 | ±0.4 | |
| TNF | 0.6 | 0.4 | 3.0 | 3.1 |
| ±0.3 | ±0.3 | ±0.5 | ±0.8 | |
apg per mg Bradford protein from Bio-plex immunoassays and as shown in Table 1. bΔΔCt relative to housekeeping genes (GAPDH and UBC) based on real time RT-PCR using SYBR green uniplex chemistry. *P < 0.05, **P < 0.01, ***P < 0.001 as compared to control. cvalues <0.1 pg/mg Bradford protein considered not detectable
Summary of top-scored features from reports of enrichment and pathways-networks analysis
| Analysis | Description of the process ( | Candidatesd |
|---|---|---|
| Gene ontology (GO) cellular processa | Inflammatory response (5.9E-12) |
|
| Immune response (6.3E-12) |
| |
| Regulation of cell proliferation (6.3E-12) |
| |
| Response to wound healing (6.4E-12) |
| |
| Cell chemotaxis (6.5E-12) | CLEC11A, | |
| Enrichment by pathways mapb | Cyto/chemokines in inflammation (3.8E-12) |
|
| Secreted signals in immune response (3.9E-12) |
| |
| Most relevant networkc | Toll-like receptor signaling pathway (2.3E-12) | IL1A, |
asources: ebi.ac.uk/quickGO/, Portal.genego.com/cgi/, and Amigo.geneontology.org/amigo
btop scored pathways were identified using input list of selected candidates showing differential levels on Metacore GeneGO portal (MetaCore Biomanual 5.0. at https://portal.genego.com/help/MetaCpre_bio_manual_5) as discussed elsewhere [11, 17, 18]. Source: portal.genego.com/
cThe cyto/chemokines displaying differential secretion following administration of AMA as shown in Table 1 used as the input list for generation of biological networks using Analyze Networks (AN) algorithm with default settings. This is a variant of the shortest paths algorithm with main parameters of (i) relative enrichment with the uploaded data from Table 1 and (ii) relative saturation of networks with canonical pathways. These networks are built on the fly and unique for the uploaded data. In this workflow the networks are prioritized based on the number of fragments of canonical pathways on the network as discussed elsewhere [17, 18]. Source: Portal.genego.com/
dCyto/chemokines detected in all groups. The negatively affected candidates by AMA are shown in italics and positively affected ones are shown in bold
Fig. 4A snapshot of the top-scored pathway map based on the enrichment distribution sorted by ‘Statistically Significant Maps’ set using Metacore portal. This pathway map was retrieved from the significant pathways involved in inflammatory responses. Experimental data from all files is linked to and visualized on the maps as thermometer like figures (red, down-regulated signals; blue, no change) to indicate vector component of the cytokine expression in the treatment groups. The cluster of cyto/chemokines which were markedly affected by AMA in the present study are shown in enclosures with broken red lines. B, binding; CM, covalent modification; Cn, competition; CS, complex subunit; IE, influence on expression; +P, phosphorylation; T, transformation; TR, transcription regulation; Z, catalysis. Green denotes positive effect. Red denotes negative effect
Fig. 5Schematic presentation of a model highlighting the probable mode of action of AMA on placental development. Typically, Toll-like receptors (TLRs) mediated action in cytotrophoblasts under the influence of adequate stimuli from decidual cells, T-cells, B-cells, macrophages and NK cells at maternal-fetal interface results in elaboration of a group of cyto/chemokines (CCL2, CCL3, CCL5, CXCL10, IL1, IL6, IL16, IL-2RA, MIF and TNF) which are associated with inflammatory and tolerogenic activities. Substantial evidence suggests that Toll-like receptor signaling pathway involving IL1, IL6, and TNF is critical during early placental development. As shown, many of these cytokines via specific receptors and associated molecules with down-stream engagement of effector moieties (e.g., NF-kB, ERK, MAPK, IP3, DAG and p53) regulate different cellular processes (e.g., inflammatory responses, cell survival, growth, proliferation, migration and apoptosis) on homotypic and heterotypic cells as shown by dashed arrows. The helical peptide like AMA with cationic moieties negatively affects the above-mentioned process at multiple levels as shown by gray arrows. Thus, AMA peptides putatively affect a variety of different cellular outcomes, depending upon the peptide concentrations and the nature of its interactions with cell membranes and membrane proteins, resulting in inadequacy of cellular homeostasis. The cytokines upregulated by AMA are shown in blue italics and down-regulated ones by AMA are shown in red italics. For further details, see the Discussion section and relevant references [12, 19, 21–32, 45–47, 49, 65, 69–71]